Retinoblastoma

1)     Abramson, D. H., & Shields, C. L. (2023). Re: Tomar et al.: American Joint Committee on Cancer Ophthalmic Oncology Task Force. High-risk pathologic features based on presenting findings in advanced intraocular retinoblastoma: A multicenter, international data-sharing American Joint Committee on Cancer study (Ophthalmology, 2022; 129:923–932). Ophthalmology, 130(2), e87–e88. https://doi.org/10.1016/j.ophtha.2022.10.024

2)     Tomar, A. S., Finger, P. T., Gallie, B. L., Wilson, M. W., Chantada, G. L., Zhao, J., ... & Mallipatna, A. (2022). Metastatic death based on presenting features and treatment for advanced intraocular retinoblastoma: A multicenter registry-based study. Ophthalmology, 130(3), 262–274. https://doi.org/10.1016/j.ophtha.2022.10.018

3)     Vempuluru, V. S., Maniar, A., & Kaliki, S. (2024). Global retinoblastoma studies: A review. Clinical & Experimental Ophthalmology, 52(3), 334–354. https://doi.org/10.1111/ceo.14357

4)     Honavar, S. G., & Rao, R. (2019). Enucleation and exenteration. In S. Chaugule, S. Honavar, & P. Finger (Eds.), Surgical Ophthalmic Oncology (pp. 203–221). Springer. https://doi.org/10.1007/978-3-030-18757-6_12

5)     Shields, C. L., Shields, J. A., Cater, J., De Potter, P., Toth, K., & Meehan, K. (2001). Plaque radiotherapy for retinoblastoma: Long-term tumor control and treatment complications in 208 tumors. Ophthalmology, 108(11), 2116–2121. https://doi.org/10.1016/S0161-6420(01)00812-4

6)     Merchant, T. E., Gould, C. J., Wilson, M. W., Kun, L. E., Pratt, C. B., & Haik, B. G. (2004). Episcleral plaque brachytherapy for retinoblastoma. Pediatric Blood & Cancer, 43(2), 134–139. https://doi.org/10.1002/pbc.20044

7)     Shields, C. L., Mashayekhi, A., Sun, H., Thangappan, A., & Shields, J. A. (2006). Iodine 125 plaque radiotherapy as salvage treatment for retinoblastoma recurrence after chemoreduction in 84 tumors. Ophthalmology, 113(11), 2087–2092. https://doi.org/10.1016/j.ophtha.2006.06.024

8)     Francis, J. H., Levin, A. M., Zabor, E. C., Gobin, Y. P., Dunkel, I. J., & Abramson, D. H. (2018). Ten-year experience with ophthalmic artery chemosurgery: Ocular and recurrence-free survival. PLoS ONE, 13(5), e0197081. https://doi.org/10.1371/journal.pone.0197081

9)     Yousef, Y. A., Soliman, S. E., Astudillo, P. P. P., Gallie, B. L., & Dimaras, H. (2016). Intra-arterial chemotherapy for retinoblastoma: A systematic review. JAMA Ophthalmology, 134(5), 584–591. https://doi.org/10.1001/jamaophthalmol.2016.0403

10) Shields, C. L., Kaliki, S., Al-Dahmash, S. A., Rojanaporn, D., Bianciotto, C., & Shields, J. A. (2013). Management of advanced retinoblastoma with intravenous chemotherapy then intra-arterial chemotherapy as alternative to enucleation. Retina, 33(10), 2103–2109. https://doi.org/10.1097/IAE.0b013e31829d1c75

11) Francis, J. H., Abramson, D. H., Gaillard, M. C., Marr, B. P., Beck-Popovic, M., Munier, F. L., ... & Gobin, Y. P. (2015). The classification of vitreous seeds in retinoblastoma and response to intravitreal melphalan. Ophthalmology, 122(6), 1173–1179. https://doi.org/10.1016/j.ophtha.2015.02.001

12) Shields, C. L., Manjandavida, F. P., Arepalli, S., Kaliki, S., & Shields, J. A. (2014). Intravitreal melphalan for persistent or recurrent retinoblastoma vitreous seeds: Preliminary results. JAMA Ophthalmology, 132(3), 319–325. https://doi.org/10.1001/jamaophthalmol.2013.8001

13) Kaliki, S., Shields, C. L., Rojanaporn, D., Al-Dahmash, S. A., Nagaiah, G., & Shields, J. A. (2013). High-risk retinoblastoma based on International Classification of Retinoblastoma: Analysis of 519 enucleated eyes. Ophthalmology, 120(5), 997–1003. https://doi.org/10.1016/j.ophtha.2012.10.032

14) Chantada, G. L., Doz, F., Orjuela, M., Qaddoumi, I., Sitorus, R. S., Kepak, T., ... & Rodriguez-Galindo, C. (2008). World disparities in risk definition and management of retinoblastoma: A report from the International Retinoblastoma Staging Working Group. Pediatric Blood & Cancer, 50(3), 692–694. https://doi.org/10.1002/pbc.21427

15) Murphree, L. M. (2005). Intraocular retinoblastoma: The case for a new group classification. Ophthalmology Clinics of North America, 18(1), 41–53. https://doi.org/10.1016/j.ohc.2004.10.002

16) Munier, F. L. (2014). Classification and management of seeds in retinoblastoma. Ophthalmic Genetics, 35(4), 193–207. https://doi.org/10.3109/13816810.2014.973045

17) Shields, C. L., Honavar, S. G., Shields, J. A., Demirci, H., Meadows, A. T., & Naduvilath, T. J. (2002). Factors predictive of recurrence of retinal tumors, vitreous seeds, and subretinal seeds following chemoreduction for retinoblastoma. Archives of Ophthalmology, 120(4), 460–464. https://doi.org/10.1001/archopht.120.4.460

18) Warda, O., Naeem, Z., Roelofs, K. A., Sagoo, M. S., & Reddy, M. A. (2023). Retinoblastoma and vision. Eye, 37(5), 797–808. https://doi.org/10.1038/s41433-021-01845-y

19) Dimaras, H., Kimani, K., Dimba, E. A. O., Gronsdahl, P., White, A., Chan, H. S. L., & Gallie, B. L. (2015). Retinoblastoma. The Lancet, 386(9997), 803–812. https://doi.org/10.1016/S0140-6736(14)60345-0

20) Fabian, I. D., Stacey, A. W., Chowdhury, T., Duncan, C., Taktak, A., Scheimberg, I., ... & Reddy, M. A. (2019). Global retinoblastoma presentation and analysis by national income level. JAMA Oncology, 5(6), 865–873. https://doi.org/10.1001/jamaoncol.2019.0266

21) Khurana, A., Eisenhut, C. A., Wan, W., et al. (2013). Comparison of the diagnostic value of MR imaging and ophthalmoscopy for the staging of retinoblastoma. European Radiology, 23(5), 1271–1280. https://doi.org/10.1007/s00330-012-2707-8

22) de Graaf, P., Göricke, S., Rodjan, F., Galluzzi, P., Maeder, P., Castelijns, J. A., ... & Moll, A. C. (2012). Guidelines for imaging retinoblastoma: Imaging principles and MRI standardization. Pediatric Radiology, 42(1), 2–14. https://doi.org/10.1007/s00247-011-2202-2

23) Cho, S. J., Kim, J. H., Baik, S. H., Sunwoo, L., Bae, Y. J., & Choi, B. S. (2020). Diagnostic performance of MRI of post-laminar optic nerve invasion detection in retinoblastoma: A systematic review and meta-analysis. Neuroradiology, 63(4), 499–509.

24) Chantada, G. L., Sampor, C., Bosaleh, A., Solernou, V., Fandiño, A., & de Dávila, M. T. (2013). Comparison of staging systems for extraocular retinoblastoma: Analysis of 533 patients. JAMA Ophthalmology, 131(9), 1127–1134. https://doi.org/10.1001/jamaophthalmol.2013.260

25) Tomar, A. S., Finger, P. T., Gallie, B., et al. (2022). Metastatic death based on presenting features and treatment for advanced intraocular retinoblastoma: A multicenter registry-based study. Ophthalmology, 129(8), 933–945.

26) Bakhshi, S., Meel, R., Kashyap, S., & Sharma, S. (2011). Bone marrow aspirations and lumbar punctures in retinoblastoma at diagnosis. Journal of Pediatric Hematology/Oncology, 33(5), e182–e185.

27) Munier, F. L., Beck-Popovic, M., Chantada, G. L., Cobrinik, D., Kivelä, T. T., Lohmann, D., ... & Stathopoulos, C. (2019). Conservative management of retinoblastoma: Challenging orthodoxy without compromising the state of metastatic grace. Progress in Retinal and Eye Research, 73, 100764. https://doi.org/10.1016/j.preteyeres.2019.05.005

28) Gombos, D. S., & Skalet, A. H. (2024a). Screening children at risk for retinoblastoma. In Clinical Ophthalmic Oncology (pp. 289–291). Springer. https://doi.org/10.1007/978-3-031-77177-4_30

29) Berry, J. L., Kogachi, K., Aziz, H. A., et al. (2017). Risk of metastasis and orbital recurrence in advanced retinoblastoma eyes treated with systemic chemoreduction versus primary enucleation. Pediatric Blood & Cancer, 64(4), e26270. https://doi.org/10.1002/pbc.26270

30) Chantada, G., Luna-Fineman, S., Sitorus, R. S., Kruger, M., Israels, T., Leal-Leal, C., et al. (2013). SIOP-PODC recommendations for graduated-intensity treatment of retinoblastoma in developing countries. Pediatric Blood & Cancer, 60(5), 719–727. https://doi.org/10.1002/pbc.24456

31) Shields, C. L., & Shields, J. A. (2010). Retinoblastoma management: Advances in enucleation, intravenous chemoreduction, and intra-arterial chemotherapy. Current Opinion in Ophthalmology, 21(3), 203–212. https://doi.org/10.1097/ICU.0b013e328338676a

32) Chantada, G. L., Guitter, M. R., Fandiño, A. C., Raslawski, E. C., de Davila, M. T. G., Vaiani, E., & Scopinaro, M. J. (2008). Treatment results in patients with retinoblastoma and invasion to the cut end of the optic nerve. Pediatric Blood & Cancer, 52(2), 218–222. https://doi.org/10.1002/pbc.21735

33) Aerts, I., Sastre-Garau, X., Savignoni, A., et al. (2013). Results of a multicenter prospective study on the postoperative treatment of unilateral retinoblastoma after primary enucleation. Journal of Clinical Oncology, 31(11), 1458–1463. https://doi.org/10.1200/JCO.2012.42.3962

34) Shah, R., & Gombos, D. S. (2024). Children’s Oncology Group (COG) trials for retinoblastoma. In J. L. Berry, B. E. Damato, & A. D. Singh (Eds.), Clinical Ophthalmic Oncology. Springer. https://doi.org/10.1007/978-3-031-77177-4_31

35) Rodriguez-Galindo, C., Orbach, D. B., & VanderVeen, D. (2015). Retinoblastoma. Pediatric Clinics of North America, 62(1), 201–223. https://doi.org/10.1016/j.pcl.2014.09.014

36) Ancona-Lezama, D., Dalvin, L. A., & Shields, C. L. (2020). Modern treatment of retinoblastoma: A 2020 review. Indian Journal of Ophthalmology, 68(11), 2356–2365. https://doi.org/10.4103/ijo.IJO_721_20

37) Dunkel, I. J., Piao, J., Chantada, G. L., Banerjee, A., Abouelnaga, S., Buchsbaum, J. C., ... & Chintagumpala, M. M. (2022). Intensive multimodality therapy for extraocular retinoblastoma: A children’s oncology group trial (ARET0321). Journal of Clinical Oncology, 40(33), 3839–3847. https://doi.org/10.1200/jco.21.02337

38) Skalet, A. H., Gombos, D. S., Gallie, B. L., Kim, J. W., Shields, C. L., Marr, B. P., Plon, S. E., & Chévez-Barrios, P. (2018). Screening children at risk for retinoblastoma: Consensus report from the American Association of Ophthalmic Oncologists and Pathologists. Ophthalmology, 125(3), 453–458.https://doi.org/10.1016/j.ophtha.2017.09.001

39) Reddy, M. A., Butt, M., Hinds, A. M., Duncan, C., Price, E. A., Sagoo, M. S., & Onadim, Z. (2021). Prognostic Information for Known Genetic Carriers of RB1 Pathogenic Variants (Germline and Mosaic). Ophthalmology. Retina, 5(4), 381–387. https://doi.org/10.1016/j.oret.2020.08.010

40) Shinohara, E. T., DeWees, T., & Perkins, S. M. (2014). Subsequent malignancies and their effect on survival in patients with retinoblastoma. Pediatric Blood & Cancer, 61(1), 116–119. https://doi.org/10.1002/pbc.24714

41) Temming, P., Arendt, M., Viehmann, A., et al. (2017). Incidence of second cancers after radiotherapy and systemic chemotherapy in heritable retinoblastoma survivors: A report from the German reference center. Pediatric Blood & Cancer, 64(1), 71–80. https://doi.org/10.1002/pbc.26193